247.79
3.34%
8.01
시간 외 거래:
247.79
전일 마감가:
$239.78
열려 있는:
$244.54
하루 거래량:
961.35K
Relative Volume:
1.15
시가총액:
$36.40B
수익:
$4.81B
순이익/손실:
$1.11B
주가수익비율:
32.82
EPS:
7.55
순현금흐름:
$1.35B
1주 성능:
+8.29%
1개월 성능:
+4.43%
6개월 성능:
+21.97%
1년 성능:
+43.61%
Resmed Inc Stock (RMD) Company Profile
명칭
Resmed Inc
전화
(858) 746-2400
주소
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
RMD을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
RMD
Resmed Inc
|
247.79 | 36.40B | 4.81B | 1.11B | 1.35B | 7.55 |
ISRG
Intuitive Surgical Inc
|
604.12 | 215.18B | 7.87B | 2.24B | 586.00M | 6.22 |
BDX
Becton Dickinson Co
|
240.37 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
ALC
Alcon Inc
|
88.54 | 43.79B | 9.76B | 1.16B | 665.00M | 2.34 |
WST
West Pharmaceutical Services Inc
|
344.69 | 25.00B | 2.88B | 499.60M | 321.60M | 6.74 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-01-16 | 개시 | Goldman | Buy |
2025-01-10 | 개시 | Piper Sandler | Neutral |
2024-12-13 | 개시 | Stifel | Hold |
2024-09-24 | 개시 | Robert W. Baird | Outperform |
2024-09-18 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
2024-09-04 | 다운그레이드 | Needham | Buy → Hold |
2024-06-25 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2024-06-24 | 다운그레이드 | Citigroup | Buy → Neutral |
2024-02-06 | 재개 | KeyBanc Capital Markets | Overweight |
2023-10-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2023-10-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2023-10-09 | 업그레이드 | JP Morgan | Neutral → Overweight |
2023-09-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
2023-09-06 | 업그레이드 | Needham | Hold → Buy |
2023-09-05 | 다운그레이드 | UBS | Buy → Neutral |
2023-08-01 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2023-05-23 | 개시 | UBS | Buy |
2023-04-14 | 개시 | Mizuho | Buy |
2023-01-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
2022-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
2022-10-20 | 업그레이드 | BofA Securities | Neutral → Buy |
2022-10-12 | 개시 | Jefferies | Hold |
2022-09-08 | 업그레이드 | Citigroup | Neutral → Buy |
2022-08-15 | 다운그레이드 | CLSA | Buy → Outperform |
2022-08-12 | 다운그레이드 | Citigroup | Buy → Neutral |
2022-08-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2022-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2022-06-06 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2022-04-06 | 개시 | Wolfe Research | Outperform |
2022-01-31 | 업그레이드 | Citigroup | Neutral → Buy |
2022-01-31 | 업그레이드 | Goldman | Neutral → Buy |
2022-01-28 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
2022-01-24 | 업그레이드 | BofA Securities | Underperform → Neutral |
2022-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
2022-01-13 | 업그레이드 | CLSA | Outperform → Buy |
2022-01-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
2021-12-21 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-12-06 | 업그레이드 | Macquarie | Neutral → Outperform |
2021-10-22 | 업그레이드 | CLSA | Underperform → Outperform |
2021-08-02 | 다운그레이드 | CLSA | Outperform → Sell |
2021-08-02 | 다운그레이드 | Needham | Buy → Hold |
2021-07-28 | 업그레이드 | Jefferies | Underperform → Hold |
2021-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2021-07-14 | 개시 | RBC Capital Mkts | Underperform |
2021-06-28 | 다운그레이드 | Citigroup | Buy → Neutral |
2021-06-22 | 업그레이드 | Macquarie | Neutral → Outperform |
2021-06-22 | 개시 | Robert W. Baird | Neutral |
2021-06-21 | 재확인 | Needham | Buy |
2021-06-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2021-06-09 | 업그레이드 | CLSA | Sell → Outperform |
2021-05-21 | 업그레이드 | JP Morgan | Neutral → Overweight |
2021-05-11 | 업그레이드 | Citigroup | Neutral → Buy |
2021-04-30 | 다운그레이드 | Citigroup | Buy → Neutral |
2021-03-16 | 업그레이드 | Needham | Hold → Buy |
2020-11-02 | 업그레이드 | UBS | Neutral → Buy |
2020-10-30 | 업그레이드 | JP Morgan | Underweight → Neutral |
2020-10-27 | 업그레이드 | BofA Securities | Underperform → Neutral |
2020-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-06-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2020-05-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2020-05-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
2020-02-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-02-03 | 개시 | CLSA | Underperform |
2020-01-31 | 다운그레이드 | UBS | Buy → Neutral |
2020-01-10 | 개시 | Oppenheimer | Perform |
2019-11-22 | 개시 | KeyBanc Capital Markets | Sector Weight |
2019-07-29 | 업그레이드 | UBS | Neutral → Buy |
2019-07-16 | 다운그레이드 | UBS | Buy → Neutral |
2019-05-06 | 업그레이드 | UBS | Neutral → Buy |
2019-04-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
2019-01-25 | 다운그레이드 | Goldman | Buy → Neutral |
2019-01-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2018-10-26 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2018-07-02 | 개시 | Goldman | Buy |
모두보기
Resmed Inc 주식(RMD)의 최신 뉴스
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
Should you buy CSL and ResMed shares in January? - The Motley Fool Australia
ResMed Inc (RMD) Stock Price Up 3.18% on Jan 21 - GuruFocus.com
ResMed Inc. (NYSE:RMD) Shares Sold by Addenda Capital Inc. - MarketBeat
Park Avenue Securities LLC Has $1.01 Million Stock Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
Ritholtz Wealth Management Cuts Position in ResMed Inc. (NYSE:RMD) - MarketBeat
ChartWatch ASX Scans: Pointerra, Cyclone Metals, Ingenia Communities, Macquarie Group, Resmed, Audinate, Dicker Data, Weebit Nano - MSN
Assistive Technology Market Set to Witness Significant Growth by 2025-2032: Sunrise Medical LLC., Tobii AB, - EIN News
Assenagon Asset Management S.A. Sells 14,445 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. (NYSE:RMD) Shares Sold by Assenagon Asset Management S.A. - Defense World
ResMed Gains 37.8% in a Year: What's Driving the Stock? - MSN
Integrated Investment Consultants LLC Makes New Investment in ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed (NYSE:RMD) Research Coverage Started at The Goldman Sachs Group - Defense World
1,453 Shares in ResMed Inc. (NYSE:RMD) Bought by Occidental Asset Management LLC - MarketBeat
Goldman Sachs tips ResMed shares to rocket 30% to a record high - MSN
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Goldman Sachs starts coverage on ResMed with "buy" rating - MSN
The Goldman Sachs Group Begins Coverage on ResMed (NYSE:RMD) - MarketBeat
ASX Broker Moves: Upgrades for Baby Bunting, Resmed vs Downgrades for Computershare, Monadelphous, Beach Energy - MSN
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
Peak Financial Advisors LLC Invests $2.97 Million in ResMed Inc. (NYSE:RMD) - MarketBeat
Board of the Pension Protection Fund Makes New $915,000 Investment in ResMed Inc. (NYSE:RMD) - MarketBeat
The Zacks Analyst Blog Highlights Vertiv, Goldman Sachs, ResMed, Ralph Lauren and Amazon - Yahoo Finance
Czech National Bank Raises Stock Position in ResMed Inc. (NYSE:RMD) - Defense World
ResMed shares are up 42% in a year. This shows why they could still be great value - MSN
ResMed shares are in a two-month lull. Is this a chance to buy? - MSN
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
Respiratory Devices Market Set to Witness Significant Growth by 2024-2031 | Medtronic, Hamilton Medical, - EIN News
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
Zacks.com featured highlights Chipotle Mexican Grill, ResMed and ServiceNow - Yahoo Finance
ResMed CFO Executes Stock Transaction Under Rule 10b5-1 Plan - TipRanks
Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD) - GuruFocus.com
Piper Sandler Initiates Coverage on ResMed (NYSE:RMD) - Defense World
Is There An Opportunity With ResMed Inc.'s (NYSE:RMD) 31% Undervaluation? - Yahoo Finance
Piper Sandler Initiates Coverage of ResMed (RMD) with Neutral Recommendation - MSN
ResMed CFO Brett Sandercock sells shares worth $234,040 By Investing.com - Investing.com Australia
ResMed CFO Brett Sandercock sells shares worth $234,040 - Investing.com India
ResMed Inc. stock outperforms market despite losses on the day - MarketWatch
Piper Sandler Begins Coverage on ResMed (NYSE:RMD) - MarketBeat
Piper Sandler starts ResMed stock at Neutral, says execution rock solid By Investing.com - Investing.com South Africa
Piper Sandler starts ResMed stock at Neutral, says execution rock solid - Investing.com India
What 5 Analyst Ratings Have To Say About ResMed - Benzinga
ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025 - GlobeNewswire
Sleep Study Equipment Market Seeking Excellent Growth | ResMed, - openPR
ResMed Inc. (NYSE:RMD) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
ResMed Inc. (NYSE:RMD) Given Average Recommendation of “Hold” by Brokerages - Defense World
Resmed Inc Officer Plans Further Sale of Common Shares - TipRanks
ResMed (RMD) is an Incredible Growth Stock: 3 Reasons Why - MSN
Here's Why ResMed (RMD) is a Strong Growth Stock - MSN
Birch Capital Management LLC Raises Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
Nordea Investment Management AB Acquires 215,561 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
Resmed Inc (RMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):